Biobetter jointly developed with Ildong, ‘ublituximab’ completed part 1 of Phase 2 clinical trial
The development of ‘ublituximab(TG-1101),’ a TG Therapeutics’ monoclonal antibody biobetter, jointly conducted with Ildong Pharmaceutical(CEO Woong-Seup Yoon), passed the part 1 of the Phase 2 clinical trial in the U.S.
Ildong Pharmaceutical quoted the recent announcement of the original develop...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.